A Phase III Trial of With Marizomib in Patients With Newly Diagnosed Glioblastoma
|
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details. |
| ClinicalTrials.gov Identifier: NCT03345095 |
|
Recruitment Status :
Recruiting
First Posted : November 17, 2017
Last Update Posted : June 17, 2019
|
Sponsor:
European Organisation for Research and Treatment of Cancer - EORTC
Collaborators:
Celgene
Canadian Cancer Trials Group
Information provided by (Responsible Party):
European Organisation for Research and Treatment of Cancer - EORTC
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
No Study Results Posted on ClinicalTrials.gov for this Study
| Recruitment Status : | Recruiting |
|---|---|
| Estimated Primary Completion Date : | July 2022 |
| Estimated Study Completion Date : | July 2023 |